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AbstrAct
Microscopic colitis (MC) is a treatable cause 
of chronic, non-bloody, watery diarrhoea, but 
physicians (particularly in primary care) are less 
familiar with MC than with other causes of 
chronic diarrhoea. The colon in patients with 
MC is usually macroscopically normal. MC can 
only be diagnosed by histological examination 
of colonic biopsies (subepithelial collagen band 
>10 µm (collagenous colitis) or >20 intraepithelial 
lymphocytes per 100 epithelial cells (lymphocytic 
colitis), both with lamina propria inflammation). 
The UK National Health Service exerts downward 
pressure to minimise colonoscopy referrals. 
Furthermore, biopsies are often not taken 
according to guidelines. These factors work against 
MC diagnosis. In this review, we note the high 
incidence of MC (comparable to ulcerative colitis 
and Crohn’s disease) and its symptomatic overlap 
with irritable bowel syndrome. We also highlight 
problems with the recommendation by National 
Health Service/National Institute for Health and 
Care Excellence guidelines for inflammatory 
bowel diseases that colonoscopy referrals should 
be based on a faecal calprotectin level of ≥100 
µg/g. Faecal calprotectin is <100 µg/g in over half 
of individuals with active MC, building into the 
system a propensity to misdiagnose MC as irritable 
bowel syndrome. This raises important questions—
how many patients with MC have already been 
misdiagnosed, and how do we address this silent 
burden? Clarity is needed around pathways for 
MC management; MC is poorly acknowledged 
by the UK healthcare system and it is unlikely 
that best practices are being followed adequately. 
There is an opportunity to identify and treat 
patients with MC more effectively.
IntroductIon
The underdiagnosis of microscopic colitis 
(MC) represents a lost opportunity for 
patients and clinicians. In many national 
settings, because of downward pressure 
to minimise specialist referrals and colo-
noscopies with histology in patients with 
seemingly normal endoscopic appear-
ances, the systems for diagnosing and 
managing patients with gastrointestinal 
problems work against a diagnosis of MC 
and its effective management.
When first described in 1980, MC 
was thought to be a rare condition.1 We 
now know that MC is a common form of 
inflammatory bowel disease (IBD), with 
one recent study putting the incidence in 
the UK at around 18 cases per 100 000 
population/year.2 The incidence of MC in 
the USA and the UK has been increasing, 
though it may have stabilised in the 
USA.2–4 Reasons for the growing incidence 
of MC may include greater awareness 
and the ageing population. Importantly, 
MC accounts for approximately 10% of 
individuals who present with non-bloody 
diarrhoea,5 but physicians, particularly in 
primary care, are not as aware of MC as a 
cause of this symptom as they are of other 
IBDs and irritable bowel syndrome (IBS). 
This is perhaps not surprising, consid-
ering that the UK National Health Service 
(NHS)6 refers to MC as a ‘less common 
type of IBD’, despite the UK incidence 
being comparable to ulcerative colitis and 
Crohn’s disease (both around 10 cases per 
100 000 population/year).7 8
The defining symptom of MC is chronic 
or recurrent, non-bloody, watery diar-
rhoea.9 Known risk factors include older 
age,3 female sex,3 smoking10 and the 
use of some drugs.11 The natural course 
of MC is generally benign, with similar 
mortality12 and colorectal cancer risk13–15 
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as the general population. However, chronic diar-
rhoea, combined with other possible symptoms such as 
abdominal pain, fatigue, arthralgia, myalgia, urgency, 
faecal incontinence, nocturnal defecation and weight 
loss,16–19 significantly impairs health-related quality of 
life in patients with MC.17 Treatment of symptomatic 
MC focuses on improving quality of life by targeting 
the underlying inflammation that is presumed to cause 
symptoms.
The underestimation of MC as a cause of diarrhoea 
is creating a legacy of accumulated misdiagnoses—a 
situation made even more unpalatable by the fact that 
there is a clear path for the diagnosis and treatment of 
this burdensome disease. In this article, we provide a 
brief overview of current best practice for the diagnosis 
and treatment of MC, explore the clinical implications 
of the overlap between MC symptoms and those of 
IBS, particularly in relation to current guidance in the 
UK healthcare system for the management of IBDs, 
and ask the question ‘what needs to be done now?’
Mc dIAgnosIs requIres hIstologIcAl 
exAMInAtIon of colonIc bIopsIes
Histological assessment of MC needs to be based on 
stepped biopsies of the colon, with a minimum of two 
biopsies taken from each of the ascending, transverse 
and descending/sigmoid colon in separate specimen 
containers. MC occurs in two histologically distinct 
forms: collagenous colitis (CC) and lymphocytic colitis 
(LC). In both CC and LC, inflammation in the lamina 
propria is present throughout the entire colon.20 The 
key histological feature distinguishing CC is the pres-
ence of a broad subepithelial collagen band, >10 µm in 
thickness, immediately underneath the surface epithe-
lium.20 The key histological feature that distinguishes 
LC is an increased number of intraepithelial lympho-
cytes (IEL), with >20 IELs per 100 epithelial cells 
generally considered diagnostic.20 Another MC group 
may also exist, referred to variably in the literature as 
MC not otherwise specified,21 paucicellular LC 22 or, 
most recently, MC incomplete (MCi).23 In patients 
with MCi, the collagen layer (>5 µm) or number of 
IELs (>5 per 100 epithelial cells) is abnormal, but 
below the threshold for CC or LC, though there is still 
inflammation in the lamina propria.20
Patients with CC, LC and MCi cannot be distin-
guished from each other based on their demographic 
features, clinical characteristics or symptom presen-
tation.23–25 Treatment guidelines do not distinguish 
between CC and LC,9 because differences in treat-
ment outcomes have not been observed between these 
subgroups.26 In addition, uncontrolled data from a 
retrospective analysis indicate that MCi has a similar 
response to treatment compared with CC and LC.23 
Interestingly, in patients with CC, the degree of lamina 
propria inflammation has been found to be a signifi-
cant predictor of the degree of symptom response,27 
leading to speculation that this feature may be of more 
diagnostic value than the criteria used to distinguish 
CC, LC and MCi. It is important to note that patients 
with MCi currently do not receive a diagnosis of MC. 
If randomised, controlled data can confirm that the 
response of MCi to treatment is similar to CC and LC, 
then it seems clear that patients with MCi should be 
classified as MC and treated accordingly. This would 
also simplify diagnosis, because pathologists have more 
trouble consistently discriminating MCi from CC and 
LC than they do discriminating between MC/MCi and 
non-MC.28
Several approaches have been used to try and mini-
mise the need for colonoscopy with biopsy for the 
diagnosis of MC. One approach is the development 
of scoring systems that use demographic and symptom 
data to identify patients at ‘low’ risk of having MC. 
Some of these scoring systems have shown promise.29–32 
However, as pointed out in a recent review, none have 
been fully validated and their utility thus remains 
conceptual.33 Numerous potential biomarkers for MC 
have been explored but none are diagnostic.34 Simi-
larly, macroscopic findings in patients with MC have 
been described, and are present in around one-third of 
patients,35 but are not specific to the condition. Histo-
logical assessment of colonic biopsies thus remains the 
only way to diagnose MC. Importantly, a major barrier 
to the assessment of colonic biopsies in patients with 
MC is its symptomatic overlap with IBS.
Mc cAn be MIsdIAgnosed As Ibs
Concomitant abdominal pain is often present in 
patients with MC (41%–52% overall, and 74%–82% in 
patients with active disease16–18) and around one-third 
to one-half36 37 of patients who present with MC meet 
symptom criteria for IBS. The hidden burden of MC 
among patients incorrectly diagnosed with (and treated 
for) IBS is potentially very large. The prevalence of IBS 
across North America, Europe and Australasia is esti-
mated at around 7% of the general population.38 Based 
on previous estimates, around 40% of these patients 
would have diarrhoea-predominant IBS (IBS-D),39 or 
around 1.7 million cases in the UK. The prevalence of 
MC in patients meeting diagnostic criteria for IBS-D 
is nearly 10%,37 or 170 000 patients if applied to the 
UK. A lack of familiarity with MC compared with IBS, 
particularly in primary care where most IBS diagnoses 
are made, means that many of those 170 000 MC cases 
might have been diagnosed as IBS-D. Patients with MC 
without concomitant abdominal pain (obligatory for an 
IBS diagnosis)40 may still receive an IBS diagnosis or the 
diagnosis of ‘functional diarrhoea’ if their physician’s 
familiarity with both MC and diagnostic criteria for 
functional bowel diseases is low. The latter may be quite 
common, with only 2%–36% of primary care physi-
cians in a recent review reporting awareness of Rome 
or Manning IBS criteria.41 In addition, some treating 
physicians may be unfamiliar with MC, but sufficiently 
familiar with IBS criteria to exclude an IBS diagnosis. 
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Table 1 Differences in clinical history between patients with 
irritable bowel syndrome and those with microscopic colitis
Clinical history variable
irritable bowel 
syndrome Microscopic colitis
First occurrence of disease Usually before 50 
years of age
Usually after 50 years 
of age
Stool consistency Soft‒variable‒hard Watery/soft
Abdominal pain/discomfort Obligatory Variable
Nocturnal diarrhoea Very unlikely Possible
Feeling of incomplete 
bowel evacuation
Common No
Weight loss Rare Common
Faecal incontinence Rare Common
Feeling of fullness/bloating Common Rare
Accompanying 
autoimmune disease
Rare Common
Figure 1 Per patient faecal calprotectin concentrations during active 
and treated/inactive collagenous colitis. Dashed line indicates the UK 
National Health Service (NHS) recommended cut-off for referral to 
colonoscopy,48 which is based on National Institute for Health and 
Care Excellence (NICE) guidelines for inflammatory bowel diseases 
(adapted from Wildt et al [50]).
Given the wide range of conditions that can present 
with chronic diarrhoea,42 patients in this situation may 
face a long and frustrating road to a correct diagnosis 
and treatment, though this may still be preferable to 
being locked into a diagnosis of IBS, which excludes the 
possibility of more appropriate treatment. It is worth 
noting that UK primary care physicians frequently diag-
nose IBS-D without specialist referral.43 Once an IBS-D 
diagnosis is made, empirical treatment is often initi-
ated without further consideration of potential organic 
causes.44
Patients with MC have a clinical history that is usually 
distinct from that of patients with IBS (table 1). In 
contrast to IBS, MC is most common in older individ-
uals (>50 years) and produces diarrhoea that is consis-
tently watery/soft, leading to imperative urgency that 
can result in faecal incontinence.45 46 Nocturnal stools 
may occur and weight loss is common. MC is often 
accompanied by autoimmune diseases such as rheu-
matic disease, thyroid disease, diabetes mellitus and 
coeliac disease.45 46 Indeed, patients with coeliac disease 
and MC can still have diarrhoea even if they are on a 
gluten-free diet, as long as MC remains untreated.47 In 
contrast to MC, IBS occurs most commonly in younger 
individuals (<50 years), produces stool of varying 
consistency, and faecal incontinence and nocturnal 
stools are rare.40 45 46 Unlike MC, IBS is also frequently 
associated with feelings of fullness/bloating and incom-
plete bowel evacuation.45 46 In most cases, by taking 
a thorough history (table 1) and using bowel diaries 
for 1–2 weeks, it is possible to distinguish between IBS 
and MC. Nevertheless, the most pragmatic approach 
is to refer patients for a colonoscopy with biopsy for 
the assessment of MC if they have chronic (>4 weeks), 
mainly watery diarrhoea, irrespective of their age and 
gender. As already discussed, histological examination 
of colonic biopsies is still the only way to confirm a 
diagnosis of MC.
downwArd pressure on referrAl Is A 
bArrIer to Mc dIAgnosIs
It is a problem for the diagnosis of MC that NHS 
primary care guidelines for referral to colonoscopy for 
IBDs,48 developed in light of updated National Institute 
for Health and Care Excellence (NICE) recommenda-
tions,49 are currently based on faecal calprotectin (FC) 
levels, and make no mention of MC. These recommen-
dations state that patients with an FC concentration 
below 100 µg/g should initially be treated as having 
IBS, and yet median concentrations of FC are below 
this level in active (48–80 µg/g)50 51 and inactive (26 
µg/g)50 cases of MC. A high proportion of these MC 
cases (>50% of those with active or treated/inactive 
CC)50 will be below the FC threshold required for 
colonoscopy (figure 1). This is not surprising because 
inflammation in MC mostly involves lymphocytes,20 
rather than neutrophils that produce FC. Further 
adding to the diagnostic inadequacy of FC is variation 
in the cut-offs that must be applied, depending on the 
FC assay method used.52 Even in patients with MC 
who do happen to have FC levels above the threshold 
for referral to colonoscopy, MC may not be correctly 
investigated, especially without prior suspicion of 
MC. Indeed, according to a recent study, only 19.5% 
of colonoscopies performed at two UK hospitals for 
the investigation of chronic diarrhoea were conducted 
according to British Society of Gastroenterology 
biopsy guidelines for the exclusion of MC, with the 
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Figure 2 Pathways to misdiagnosis of microscopic colitis as irritable bowel syndrome in patients who present to a UK primary care physician with 
chronic diarrhoea. aOutcome assumes biopsiesb and histopathological assessment of MC is performed optimally. bOptimal biopsies for MC detection 
defined as stepped biopsies of the colon, with a minimum of two biopsies taken from each of the ascending, transverse and descending/sigmoid 
colon in separate specimen containers. CD, Crohn’s disease; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; MC, microscopic colitis; 
NHS, National Health Service; PCP, primary care physician; UC, ulcerative colitis.
rate increasing to 48% when an indication for MC was 
present.53
Guidelines for the management of lower gastrointes-
tinal symptoms in the UK reflect a general downward 
pressure on physicians, particularly general practi-
tioners, to minimise patient referrals. Current path-
ways restrict referral and colonoscopies for what are 
perceived to be non-cancer and non-IBD symptoms. 
Even where NHS guidelines do support referral, such 
as for suspected colorectal cancer, perceived pressure 
not to refer appears substantial. A recent survey of 
primary care physicians in the UK identified resource 
pressure, perceived as coming from clinical commis-
sioning groups, as one of the barriers preventing 
referral of patients meeting NICE guidelines for urgent 
referral for suspected colorectal cancer.54
While there is a need to conserve resources in 
publicly funded healthcare systems, this should not be 
at the expense of effective patient care. As it currently 
stands, the UK system militates against diagnosing 
MC (figure 2). The social and economic (eg, work 
productivity, repeat visits to the doctor) costs of this 
likely outweigh those of achieving a rapid histological 
diagnosis of MC, followed by treatment, which can be 
effective.
Mc Is A hIghly treAtAble condItIon
Initial management of MC should focus on eliminating 
(where possible) known risk factors, namely smoking10 
and certain medications (proton pump inhibitors, 
non-steroidal anti-inflammatory drugs, selective sero-
tonin reuptake inhibitors and histamine-2 receptor 
antagonists).11 Failing this approach, pharmacological 
interventions should be explored.
Current guidelines recommend treatment with the 
corticosteroid budesonide for induction and main-
tenance of remission of symptomatic MC.9 45 The 
estimated rate of clinical remission combined with 
histological improvement in patients with symptom-
atic MC treated with budesonide is 81%.45 Relapse 
occurs in around 60%‒80% of patients on cessation of 
budesonide treatment.45 In most cases, however, reini-
tiating budesonide treatment leads to clinical remis-
sion, which can be maintained with a lower dose.45
Drugs used to treat other types of IBD are also likely 
to have a role in the treatment of MC. Non-biologic 
(eg, azathioprine and 6-mercaptopurine) immunosup-
pressant drugs have been used in clinical practice in 
patients with refractory symptoms or steroid depen-
dence, and may be of benefit, but clinical trials are 
lacking.45 Similarly, biologic (anti-tumour necrosis 
factor α) immunosuppressant drugs have been used 
in patients with refractory symptoms, with poten-
tially encouraging results, but again these have not 
been assessed in clinical trials.45 The most recent clin-
ical trials of mesalamine in patients with CC and LC 
have shown this drug to be no more effective than 
placebo.55 56
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Key messages
 ► Microscopic colitis (MC) is a prevalent (comparable to 
ulcerative colitis and Crohn’s disease) but treatable 
cause of chronic, non-bloody, watery diarrhoea.
 ► The colon is macroscopically normal in most patients 
with MC; diagnosis thus requires histological 
examination of colonic biopsies.
 ► MC is less familiar to physicians (particularly in primary 
care) than other causes of chronic diarrhoea and may 
be misdiagnosed because of symptomatic overlap with 
irritable bowel syndrome (IBS), downward pressure not 
to refer patients for colonoscopy and low adherence to 
biopsy guidelines.
 ► The UK National Health Service recommends colonoscopy 
when faecal calprotectin is ≥100 µg/g, based on National 
Institute for Health and Care Excellence guidelines 
for inflammatory bowel diseases; however, faecal 
calprotectin is <100 µg/g in over 50% of patients with 
active MC.
 ► In most cases it is possible to distinguish between IBS 
and MC by taking a thorough history, though a more 
pragmatic approach is to refer patients for colonoscopy 
with biopsy to assess MC if they have chronic (>4 
weeks), mainly watery diarrhoea.
 ► A large, hidden burden of undiagnosed and untreated 
MC likely exists in the UK population owing to systemic 
misdiagnosis of MC as IBS.
 ► Pathways for the management of MC in the UK are 
unclear and need to be clarified so that they can be 
amended and standardised where necessary.
In summary, treatment options for patients with 
symptomatic MC have much to offer and should 
improve as greater awareness of MC drives new clinical 
trials to support the use of other drugs in patients with 
refractory symptoms or who are steroid dependent.
whAt needs to be done now
The issue of undiagnosed MC is mainly one of famili-
arity versus better known causes of chronic diarrhoea 
such as IBS and other IBDs, and downward pressure 
on colonoscopy investigation and specialist referral. In 
patients who present with chronic diarrhoea, MC is 
often not considered or investigated because it is not 
at the forefront of doctors’ minds and because of pres-
sure to conserve resources. Improving the detection 
of MC moving forward requires a concerted effort to 
appraise physicians of the key aspects of this condi-
tion, especially in the primary care setting where the 
fate of these patients is most likely to be determined. 
The key take home messages are as follows:
 ► MC is an IBD with an incidence similar to ulcerative 
colitis and Crohn’s disease.
 ► The defining symptom of MC is chronic (>4 weeks), 
mainly watery diarrhoea.
 ► When this defining symptom is present, an appropriate 
course of action is colonoscopy with biopsy (minimum 
of two biopsies taken from each of the ascending, trans-
verse and descending/sigmoid colon in separate tubes) 
for histological assessment of MC.
 ► FC should not be used as the basis for referral to colo-
noscopy in patients with chronic, non-bloody, mainly 
watery diarrhoea because it is not diagnostic for MC.
 ► MC is highly treatable.
In the UK, a good starting point for spreading these 
messages would include updating NICE recommenda-
tions and the information on MC currently provided 
by the NHS. A dialogue between primary care organi-
sations and secondary care providers is also needed to 
facilitate greater awareness of patients with MC.
Consideration needs to be given to patients who 
have already sought care for established symptoms 
of MC, but who have not received a diagnosis. One 
approach is to use patient records and healthcare 
databases to identify and follow-up on those patients 
most likely to have had MC misdiagnosed as IBS (eg, 
IBS-D with symptoms and factors suggestive of MC, 
no record of colonoscopy, multiple switching between 
different IBS therapies). Whatever the approach, an 
initial increase in costs related to colonoscopy referrals 
would be expected. However, these would probably 
recede as the accumulated burden of undiagnosed MC 
is gradually relieved, and be offset by reductions in the 
known direct and indirect costs of chronic diarrhoea in 
the general population.42
In addition to activities aimed at increasing the 
awareness of MC, clarification of current management 
practices in the UK is required so that they can be 
amended and standardised where necessary. Examples 
where practices are unclear for MC include responsi-
bility of care (does it lie with primary care physicians 
or gastroenterologists?), the use of stool diaries and 
disease activity criteria, the degree of patient follow-up 
and regularity of exclusion of coeliac disease, and 
whether histopathologists are sufficiently alert to MC. 
Given that MC is poorly acknowledged by the UK 
healthcare system as a prevalent cause of chronic diar-
rhoea, it seems unlikely that best practices are being 
consistently or adequately monitored.
conclusIon
The hidden burden of MC has crept up on us. Aware-
ness of MC as a prevalent, yet highly treatable cause of 
chronic diarrhoea needs to increase and the pathways 
for its management clarified. Current NHS guidelines 
do not adequately acknowledge or accommodate for 
this condition. The ability to identify and treat patients 
with MC provides an excellent opportunity to improve 
care.
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